Table 4. Percentage of subjects with growth inhibition assay activity ≥15% against FVO parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.
| Vaccine Group | |||
|---|---|---|---|
| Time point | AMA1 (%) | Control (%) | p-value1 |
| Day 0 | 159/199 (79.9) | 158/201 (78.6) | 0.75 |
| Day 30 | 144/194 (74.2) | 125/195 (64.1) | 0.031 |
| Day 60 | 123/190 (64.7) | 100/191 (52.4) | 0.014 |
| Day 90 | 140/195 (71.8) | 116/192 (60.4) | 0.018 |
| Day 150 | 170/194 (87.6) | 151/189 (79.9) | 0.040 |
| Day 240 | 144/192 (75.0) | 130/189 (68.8) | 0.18 |
| Day 364 | 168/191 (88.0) | 161/187 (86.1) | 0.59 |
| Day 547 | 158/187 (84.5) | 155/185 (83.8) | 0.85 |
| Day 730 | 170/181 (93.9) | 159/176 (90.3) | 0.21 |
| Day 0 <15%GIA; Day 90 ≥15%GIA | 18/40 (45.0) | 14/42 (33.3) | 0.28 |
| Day 0 <15%GIA; Day 364 ≥15%GIA | 33/40 (82.5) | 29/41 (70.7) | 0.21 |
| Day 0 <15%GIA; Day 730 ≥15%GIA | 34/38 (89.5) | 33/39 (84.6) | 0.53 |
1 Chi-square test with no continuity correction
2 p ≤ α* = 1–0.951/12 = 0.00427; assuming all 12 tests are independent, testing at significance level α* keeps the overall type I error rate at 0.05. There were no such p-values in this table.